scispace - formally typeset
L

Lisa Robson

Researcher at Alexandra Hospital

Publications -  64
Citations -  2013

Lisa Robson is an academic researcher from Alexandra Hospital. The author has contributed to research in topics: Cytogenetics & Fluorescence in situ hybridization. The author has an hindex of 22, co-authored 64 publications receiving 1973 citations. Previous affiliations of Lisa Robson include Johns Hopkins University School of Medicine & Royal Prince Alfred Hospital.

Papers
More filters
Journal ArticleDOI

Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library.

TL;DR: The benefits of this system for cancer targeting based on single–chain Fv (scFv) antibodies selected from combinatorial libraries, produced in bacteria and purified by using an engineered tag are illustrated.
Journal ArticleDOI

Morbidity and mortality attributable to alcohol, tobacco, and illicit drug use in Canada

TL;DR: Substance abuse exacts a considerable toll on Canadian society in terms of morbidity and mortality, accounting for 21% of deaths, 23% of years of potential life lost, and 8% of hospitalizations.
Journal ArticleDOI

Phage libraries for generation of clinically useful antibodies

TL;DR: This work used the insertion of antibody genes into filamentous bacteriophage to produce an antibody to carcinoembryonic antigen with higher affinity and better tumour specificity than antibodies currently in use.
Journal ArticleDOI

Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography

TL;DR: A new procedure is described for the purification of an anti-carcinoembryonic antigen (CEA) single chain Fv, referred to as MFE-23, from bacterial supernatant using a simple insertion of a hexa-histidine tail fused at the C-terminus, which proved to be superior to standard CEA antigen affinity chromatography.
Journal ArticleDOI

A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules.

TL;DR: PPX is a water-soluble paclitaxel-polymer conjugate with a prolonged half-life and limited volume of distribution and dose-limiting toxicities were neutropenia and neuropathy.